Literature DB >> 8532650

Hematogenous metastases of pancreatic ductal carcinoma.

T Kamisawa1, T Isawa, M Koike, K Tsuruta, A Okamoto.   

Abstract

To investigate the heterogeneity of hematogenous metastases of pancreatic ductal carcinoma, we investigated carcinomatous spread in 130 autopsy cases. Hepatic metastases occurred most frequently, in 81 cases (62%), which may be explained by the fact that all veins draining the pancreas flow into the portal system. We closely examined the 49 cases without hepatic metastases. Sixteen patients had pulmonary metastases without hepatic metastases, whereas seven had peculiar hematogenous metastases without hepatic or pulmonary metastases. Fifteen of these 23 patients had pancreatic body carcinomas. The unusual patterns of spread might be due to (a) hepatofugal portosystemic shunting induced by splenic vein obstruction, (b) retrograde lymphatic infiltration from metastatic tracheobronchial lymph nodes, or (c) aggressive characteristics of the tumors indicated by peculiar histologic features such as pleomorphic or mucoepidermoid carcinoma, etc. Sixteen patients showed only lymph node metastases and 10 had no distant metastases. Seventeen of these 26 cases had pancreatic head carcinoma. Histologically, two patients had mucinous cystadenocarcinomas, and six had adenocarcinomas producing rich mucin. The average age of the group with no distant metastases was higher.

Entities:  

Mesh:

Year:  1995        PMID: 8532650     DOI: 10.1097/00006676-199511000-00005

Source DB:  PubMed          Journal:  Pancreas        ISSN: 0885-3177            Impact factor:   3.327


  56 in total

1.  An Unusual Finding on Screening Colonoscopy-Pancreatic Cancer.

Authors:  Diana L Franco; Suresh Pola; Derek Patel
Journal:  J Gastrointest Cancer       Date:  2012-09

Review 2.  The role of radiotherapy in locally advanced pancreatic carcinoma.

Authors:  Ruchika Gutt; Stanley L Liauw; Ralph R Weichselbaum
Journal:  Nat Rev Gastroenterol Hepatol       Date:  2010-07-13       Impact factor: 46.802

Review 3.  The lymphatic system and pancreatic cancer.

Authors:  Darci M Fink; Maria M Steele; Michael A Hollingsworth
Journal:  Cancer Lett       Date:  2015-12-29       Impact factor: 8.679

4.  Primary Recurrence in the Lung is Related to Favorable Prognosis in Patients with Pancreatic Cancer and Postoperative Recurrence.

Authors:  Biao Zheng; Kenoki Ohuchida; Zilong Yan; Takashi Okumura; Takao Ohtsuka; Masafumi Nakamura
Journal:  World J Surg       Date:  2017-11       Impact factor: 3.352

Review 5.  Metastasis Organotropism: Redefining the Congenial Soil.

Authors:  Yang Gao; Igor Bado; Hai Wang; Weijie Zhang; Jeffrey M Rosen; Xiang H-F Zhang
Journal:  Dev Cell       Date:  2019-05-06       Impact factor: 12.270

Review 6.  Oligometastatic Disease in Pancreatic Cancer - How to Proceed?

Authors:  Bernhard W Renz; Stefan Boeck; Falk Roeder; Christoph Trumm; Volker Heinemann; Jens Werner
Journal:  Visc Med       Date:  2017-02-10

7.  Five-Fraction Stereotactic Body Radiation Therapy (SBRT) and Chemotherapy for the Local Management of Metastatic Pancreatic Cancer.

Authors:  Jonathan W Lischalk; Aidan Burke; Jessica Chew; Christen Elledge; Marie Gurka; John Marshall; Michael Pishvaian; Sean Collins; Keith Unger
Journal:  J Gastrointest Cancer       Date:  2018-06

8.  Characteristics of pancreatic carcinoma in the elderly.

Authors:  T Kamisawa; T Yuyang; N Egawa; J Ishiwata; K Tsuruta; A Okamoto; M Koike
Journal:  Int J Pancreatol       Date:  1998-08

Review 9.  Process of hepatic metastasis from pancreatic cancer: biology with clinical significance.

Authors:  Haojun Shi; Ji Li; Deliang Fu
Journal:  J Cancer Res Clin Oncol       Date:  2015-08-07       Impact factor: 4.553

10.  Color-coded imaging of splenocyte-pancreatic cancer cell interactions in the tumor microenvironment.

Authors:  Michele McElroy; Sharmeela Kaushal; Michael Bouvet; Robert M Hoffman
Journal:  Cell Cycle       Date:  2008-09-26       Impact factor: 4.534

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.